Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Papillomavirus Infections 5Uterine Cervical Neoplasms 3Condylomata Acuminata 2Vulvar Neoplasms 1Virus Diseases 1Vaginal Neoplasms 1Anus Neoplasms 1

Interventions

Radiotherapy 5Brachytherapy 3tremelimumab 2fludarabine 2durvalumab 2aflibercept 2Trastuzumab 2Topotecan 2Radiosurgery 2Radiation 2Magnetic Resonance Spectroscopy 2Cyclophosphamide 2Cisplatin 2Capecitabine 2tipifarnib 1temsirolimus 1talazoparib 1entinostat 1adavosertib 1Vinorelbine 1Vaccines 1Therapeutics 1Platinum 1Pharmacogenomic Testing 1Papillomavirus Vaccines 1Paclitaxel 1Interleukin-12 Subunit p35 1Interleukin-12 1Immunoglobulin G 1Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Vaginal Neoplasms × Papillomavirus Vaccines × Clear all
NCT05680454 2023-01-17

A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine

Beijing Health Guard Biotechnology, Inc

Phase 1 Completed
160 enrolled
GastrointestinalGynecologic

Anus Neoplasms, Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡